成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Fenofibrate and Dyslipidemia: Still a Place in Therapy?

Published:1 September 2018 DOI: 10.1007/s40265-018-0965-8 PMID: 30159817
Nicola Tarantino, Francesco Santoro, Michele Correale, Luisa De Gennaro, Silvio Romano, Matteo Di Biase, Natale Daniele Brunetti

Abstract

Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fenofibrate 49562-28-9 C20H21ClO4 714 suppliers $5.00-$546.00

Similar articles

IF:2.8

Gibberellic acid in plant: still a mystery unresolved.

Plant Signaling & Behavior Ramwant Gupta, S K Chakrabarty,etc Published: 1 September 2013
IF:13

Fenofibrate: a review of its use in dyslipidaemia.

Drugs Kate McKeage, Gillian M Keating,etc Published: 1 October 2011
IF:0

Place of alfacalcidol in treatment of osteoporosis and osteoporotic fractures

Medical alphabet N. Toroptsova,?O. Nikitinskaya,etc Published: 25 December 2022